What is Chugai Pharmaceutical Co Revenue per Share?
Chugai Pharmaceutical Co's revenue per share for the
three
months ended in Jun. 2024 was $0.60.
Chugai Pharmaceutical Co's revenue per share for the trailing twelve months (TTM) ended in Jun. 2024 was $2.33.
Warning Sign:
Chugai Pharmaceutical Co Ltd revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue Per Share Growth Rate of Chugai Pharmaceutical Co was -12.90% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 12.20% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 16.40% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 11.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Chugai Pharmaceutical Co's Revenue per Share or its related term are showing as below:
CHGCY'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -3.4 Med: 6.55 Max: 22.4
Current: 12.2
During the past 13 years, Chugai Pharmaceutical Co's highest 3-Year average Revenue Per Share Growth Rate was 22.40% per year. The lowest was -3.40% per year. And the median was 6.55% per year.
CHGCY's 3-Year Revenue Growth Rate is ranked better than 67.36% of 910
companies
in the Drug Manufacturers industry
Industry Median: 6.4
vs CHGCY: 12.20
Chugai Pharmaceutical Co Revenue per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Chugai Pharmaceutical Co's Revenue per Share
For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chugai Pharmaceutical Co's PS Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Chugai Pharmaceutical Co's PS Ratio falls into.
Chugai Pharmaceutical Co Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Chugai Pharmaceutical Co's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.33
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chugai Pharmaceutical Co (OTCPK:CHGCY) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Chugai Pharmaceutical Co Revenue per Share Related Terms
Thank you for viewing the detailed overview of Chugai Pharmaceutical Co's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and covid-19 patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CHGCY has been successfully added to your 